An international team of researchers supported by the National Institutes of Health (NIH) has blocked staph infections in mice using a drug previously tested in clinical trials as a cholesterol-lowering agent.

Although the causes of Alzheimer's disease are not completely understood, amyloid-beta (A-beta) is widely considered a likely culprit — the "sticky" protein clumps into plaques thought to harm brain cells.

A team of researchers investigating cholesterol and lipid transport has performed experiments that cast serious doubt on the dominant hypothesis of how the body rids its cells of "bad" cholesterol (LDL) and increases "good" cholesterol (HDL).

Researchers have identified a new player in the control of so-called “good” cholesterol that circulates in the bloodstream and reduces heart attack risk, according to a report in the August issue of Cell Metabolism, a publication of Cell Press.

Scientists have shown that a protein involved in cholesterol metabolism may cause the accelerated onset of Alzheimer's Disease in individuals affected with Down Syndrome.